The Impact of Pomegranate Extract on Chronic Cardiomyopathy Complicated by Renal Insufficiency (ImPrOVE): a Pilot Study

Phase 2TerminatedNCT01102140

Jennifer Cowger , MD, MS20 enrolled

Overview

This blinded, controlled study will examine the impact of pomegranate polyphenol extract (POMx, from Pom Wonderful, LLC), 1000mg on cardiomyopathy in subjects with chronic renal insufficiency.

Heart failure (HF) is a disease of great prevalence in the U.S. with an associated high morbidity and mortality. In individuals with concomitant chronic renal insufficiency (CRI), outcomes are even worse due to pharmaceutical under treatment and higher baseline levels of oxidative stress. Reactive oxygen species (ROS) are generated during mechanoenergetic uncoupling and can cause myocardial protein, lipid, and DNA damage, leading to the development of HF. One means of preventing the progression of HF may be through ROS reduction or an improvement in systemic or local oxidative stress handling. In this randomized, single blind placebo-controlled pilot study, we hypothesize that 12 weeks of treatment with oral pomegranate extract (POMx) will lead to a reduction in oxidative stress (as assessed by measuring thiobarbituric acid-reactive substances, F8-isoprostanes, and glutathione) in subjects (n=30) with cardiomyopathy (LVEF ≤40%) and CRI (GFR \<60 ml/hr). Secondary aims include assessing the impact of POMx on myocardial remodeling and endothelial dysfunction by measuring serum collagen levels and asymmetric dimethylarginine, respectively. Findings from this study will serve as pilot data for a larger randomized trial of longer term POMx therapy in subjects with cardiomyopathy.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Cardiomyopathy Heart Failure

Interventions

POMx, pomegranate polyphenol extractDRUG

1000 mg orally once daily.

Sugar PillDRUG

Matching sugar pill

Eligibility

Sex: ALLMin age: 21 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult subjects (≥21 years of age) with cardiomyopathy (ejection fraction ≤40%) of at least 1 year duration and CRI (GFR \<60 cc/hr for at least 3 months) will be eligible for enrollment. * Subjects must have New York Heart Association (NYHA) functional class I-III symptoms and be on stable doses of HF evidence-based therapies (β-blocker, ACE inhibitor or ARBs, aldosterone inhibitor \[if appropriate\]) for at least 3 months or have a documented contraindication or intolerance to such therapy Exclusion Criteria: * Subjects admitted to a hospital for acute myocardial infarction (defined as positive troponins) or HF exacerbation within the last 6 months will not be eligible for enrollment. * Subjects on warfarin or rosuvastatin will also be excluded. * Other exclusion criteria are as follows: * HF that is deemed to be congenital or infiltrative in etiology * the presence of a life-threatening illness with a projected survival ≤6 months; ongoing infection * pregnancy * inability to follow-up * end-stage renal disease requiring dialysis * renal transplant listing * recent (within last 6 months) POMx use or intake \>8 ounces daily of pomegranate juice * known hypersensitivity to any fruit in the Punicaceae family * connective tissue or collagen vascular disease

Locations (2)

University of Michigan Health Systems

Ann Arbor, Michigan, United States

University of Michigan Health System

Ann Arbor, Michigan, United States

Outcomes

Primary Outcomes

Thiobarbituric Reactive Substances (TBARS)

This is a serum marker of oxidative stress.

Time frame: baseline and after 12 weeks

Secondary Outcomes

F-8 Isoprostanes

This is a serum marker of oxidative stress.

Time frame: Baseline and 12 weeks

Procollagen Types I (PINP) and III (PIIINP)

This is a serum marker of collagen turnover (fibrosis/scar formation).

Time frame: baseline and 12 weeks

Asymmetric Dimethylarginine (ADMA)

ADMA is a serum enzyme involved in metabolism of endothelium derived nitric oxide (NO). NO's has an important role in maintaining endothelial homeostasis. Elevated ADMA levels suggest impaired endothelial function.

Time frame: baseline and 12 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.